Glycomimetics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Crescent Biopharma, Inc. has announced its 2026 Annual General Meeting of Shareholders, scheduled for June 2, 2026, to be held virtually.
GlycoMimetics and Crescent Biopharma updated their investor presentation regarding their proposed merger, highlighting Crescent's oncology pipeline and potential.
GlycoMimetics and Crescent Biopharma updated their investor presentation regarding their proposed merger on November 7, 2024, highlighting Crescent's pipeline and potential.
DEFA14A: GlycoMimetics to Acquire Crescent Biopharma in All-Stock Deal, Secures $200 Million Financing
GlycoMimetics will acquire Crescent Biopharma, pivoting to solid tumor therapeutics with a $200 million financing to advance Crescent's pipeline.
DEF 14A: GlycoMimetics Seeks Stockholder Approval for Increased Share Authorization and Officer Exculpation
GlycoMimetics is holding its annual stockholder meeting on May 1, 2024, to vote on key proposals including director elections, auditor ratification, executive compensation, increasing authorized shares, and officer exculpation.